Researchers at the new SynthX Center will aim to turn fundamental research into clinical applications and make precision adjustments to drug properties and molecules. Photo via Rice University

Rice University's new Synthesis X Center officially launched last month to bring together experts in cancer care and chemistry.

The center was born out of what started about seven years ago as informal meetings between Rice chemist Han Xiao's research group and others from the Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center at the Baylor College of Medicine. The level of collaboration between the two teams has grown significantly over the years, and monthly meetings now draw about 100 participants from across disciplines, fields and Houston-based organizations, according to a statement from Rice.

Researchers at the new SynthX Center will aim to turn fundamental research into clinical applications and make precision adjustments to drug properties and molecules. It will focus on improving cancer outcomes by looking at an array of factors, including prevention and detection, immunotherapies, the use of artificial intelligence to speed drug discovery and development, and several other topics.

"At Rice, we are strong on the fundamental side of research in organic chemistry, chemical biology, bioengineering and nanomaterials,” Xiao says in the statement. “Starting at the laboratory bench, we can synthesize therapeutic molecules and proteins with atom-level precision, offering immense potential for real-world applications at the bedside ... But the clinicians and fundamental researchers don’t have a lot of time to talk and to exchange ideas, so SynthX wants to serve as the bridge and help make these connections.”

SynthX plans to issue its first merit-based seed grants to teams with representatives from Baylor and Rice this month.

With this recognition from Rice, the teams from Xiao's lab and the TMC will also be able to expand and formalize their programs. They will build upon annual retreats, in which investigators can share unpublished findings, and also plan to host a national conference, the first slated for this fall titled "Synthetic Innovations Towards a Cure for Cancer.”

“I am confident that the SynthX Center will be a great resource for both students and faculty who seek to translate discoveries from fundamental chemical research into medical applications that improve people’s lives,” Thomas Killian, dean of the Wiess School of Natural Sciences, says in the release.

Rice announced that it had invested in four other research centers along with SynthX last month. The other centers include the Center for Coastal Futures and Adaptive Resilience, the Center for Environmental Studies, the Center for Latin American and Latinx Studies and the Rice Center for Nanoscale Imaging Sciences.

Earlier this year, Rice also announced its first-ever recipients of its One Small Step Grant program, funded by its Office of Innovation. The program will provide funding to faculty working on "promising projects with commercial potential," according to the website.

Spun out of Baylor College of Medicine, Phiogen was selected out of 670 companies to pitch at SXSW earlier this month. Photo via Getty Images

Houston startup recognized for inclusivity on journey to commercialize next-gen therapeutics

future of medicine

A new Houston biotech company won a special award at the 16th Annual SXSW Pitch Award Ceremony earlier this month.

Phiogen, one of 45 companies that competed in nine categories, was the winner for best inclusivity, much to the surprise of the company’s CEO, Amanda Burkhardt.

Burkhardt tells InnovationMap that while she wanted to represent the heavily female patient population that Phiogen seeks to treat, really she just hires the most skilled scientists.

“The best talent was the folks that we have and it ends up being we have three green card holders on our team. As far as ethnicities, we have on our team we have Indian, African-American, Korean, Chinese Pakistani, Moroccan and Hispanic people and that just kind of just makes up the people who helped us on a day-to-day basis,” she explains.

Phiogen was selected out of 670 companies to be in the health and nutrition category at SXSW.

“We did really well, but there was another company that also did really well. And so we were not selected for the pitch competition, which we were a little bummed about because I killed the pitch,” Burkhardt recalls.

But Phiogen is worthy of note, pitch competition or not. The new company spun off from research at Dr. Anthony Maresso’s TAILOR Labs, a personalized phage therapy center at Baylor College of Medicine, last June.

“Our whole goal is to create the next generation of anti-infectives,” says Burkhardt.

That means that the company is making alternatives to antibiotics, but as Burkhardt says, “We’re hoping to be better than antibiotics.”

How does it work? Bacteriophages are viruses that infect bacteria.

“You can imagine them as the predators in the bacteria world, but they don't infect humans. They don't affect animals. They only infect bacteria,” Burkhardt explains.

Phiogen utilizes carefully honed bacteriophages to attack bacteria that include the baddies behind urinary tract infection (UTI), bacteremia (bacteria in the blood), and skin wounds.

The team’s primary focus is on treatment-resistant UTI. One example was a male patient who received Phiogen’s treatment thanks to an emergency-use authorization from the FDA. The gentleman had been suffering from an infection for 20 years. He was treated with Phiogen’s bacteriophage therapy for two weeks and completely cleared his infection with no recurrence.

Amanda Burkhardt is the CEO of Phiogen. Photo via LinkedIn

But Phiogen has its sights set well beyond the first maladies it’s treated. An oft-quoted 2016 report projected that by 2050, 10 million people a year will be dying from drug-resistant infections.

“A lot of scientists call it the silent pandemic because it's happening now, we're living in it, but there's just not as much being said about it because it normally happens to people who are already in the hospital for something else, or it's a comorbidity, but that's not always the case, especially when we're talking about urinary tract infections,” says Burkhardt.

Bacteriophages are important because they can be quickly trained to fight against resistant strains, whereas it takes years and millions of dollars to develop new antibiotics. There are 13 clinical trials that are currently taking place for bacteriophage therapy. Burkhardt estimates that the treatment method will likely gain FDA approval in the next five years.

“The FDA actually has been super flexible on progressing forward. Because they are naturally occurring, there's not really a safety risk with these products,” she says.

And Burkhardt, whose background is in life-science commercialization, says there’s no better place to build Phiogen than in Houston.

“You have Boston, you have the Bay [Area], and you have the Gulf Coast,” she says. “And Houston is cheaper, the people are friendlier, and it’s not a bad place to be in the winter.”

She also mentions the impressive shadow that Helix Park will cast over the ecosystem. Phiogen will move later this year to the new campus — one of the labs selected to join Baylor College of Medicine.

And as for that prize, chances are, it won’t be Phiogen’s last.

Researchers at Baylor College of Medicine’s Human Genome Sequencing Center have trained an AI assistant to explain genetic test results to patients. Photo via Getty Images

Houston researches tap into GenAI for communicating genetic test results

hi, tech

Artificial intelligence in the health care setting has a lot of potential, and one Houston institution is looking into one particular use.

Researchers at Baylor College of Medicine’s Human Genome Sequencing Center have trained an AI assistant to explain genetic test results to patients. According to findings published in the Journal of the American Medical Informatics Association (JAMIA), the team has developed generative AI to understand and interpret genetic tests. They have also tested its accuracy against Open AI’s ChatGPT 3.5.

“We created a chatbot that can provide guidance on general pharmacogenomic testing, dosage implications, and the side effects of therapeutics, and address patient concerns,” explains first author Mullai Murugan in a press release. Murugan is director of software engineering and programming at the Human Genome Sequencing Center. “We see this tool as a superpowered assistant that can increase accessibility and help both physicians and patients answer questions about genetic test results.”

The initial chatbot training specifically targeted pharmacogenomic testing for statins, meaning a patient’s potential response to cholesterol-lowering drugs, as dictated by genetics.

Murugan explains why they decided to create their own chatbot in the key publication on statin pharmacogenomics was published in May 2022, four months after the training cutoff date for ChatGPT 3.5 in January 2022. Alternatively, her team’s technology uses Retrieval Augmented Generation (RAG) and was trained on the most recent guidelines.

How did the two AI assistants compare? Four experts on cardiology and pharmacogenomics rated both chatbots based on accuracy, relevancy, risk management, and language clarity, among other factors. Though the AI scored similarly on language clarity, Baylor’s chatbot scored 85 percent in accuracy and 81 percent in relevancy compared to ChatGPT’s 58 percent in accuracy and 62 percent in relevancy when asked questions from healthcare providers.

“We are working to fine-tune the chatbot to better respond to certain questions, and we want to get feedback from real patients,” Murugan says. “Based on this study, it is very clear that there is a lot of potential here.” Nonetheless, Murugan emphasized that there is much work still to be done before the program is ready for clinical applications. That includes training the chatbot to explain results in the language used by genetic counselors. Funds from the NIH’s All of Us Research Program helped to make the research possible.

Several Houston organizations have received millions from the Cancer Prevention and Research Institute of Texas. Photo via tmc.edu

Texas organization grants $68.5M to Houston institutions for recruitment, research

Three prominent institutions in Houston will be able to snag a trio of high-profile cancer researchers thanks to $12 million in new funding from the Cancer Prevention and Research Institute of Texas.

The biggest recruitment award — $6 million — went to the University of Texas MD Anderson Center to lure researcher Xiling Shen away from the Terasaki Institute for Biomedical Innovation in Los Angeles.

Shen is chief scientific officer at the nonprofit Terasaki Institute. His lab there studies precision medicine, including treatments for cancer, from a “systems biology perspective.”

He also is co-founder and former CEO of Xilis, a Durham, North Carolina-based oncology therapy startup that raised $70 million in series A funding in 2021. Before joining the institute in 2021, the Stanford University graduate was an associate professor at Duke University in Durham.

Shen and Xilis aren’t strangers to MD Anderson.

In 2023, MD Anderson said it planned to use Xilis’ propriety MicroOrganoSphere (MOS) technology for development of novel cancer therapies.

“Our research suggests the MOS platform has the potential to offer new capabilities and to improve the efficiency of developing innovative drugs and cell therapies over current … models, which we hope will bring medicines to patients more quickly,” Shen said in an MD Anderson news release.

Here are the two other Cancer Prevention and Research Institute of Texas (CPRIT) awards that will bring noted cancer researchers to Houston:

  • $4 million to attract David Sarlah to Rice University from the University of Illinois, where he is an associate professor of chemistry. Sarlah’s work includes applying the principles of chemistry to creation of new cancer therapies.
  • $2 million to lure Vishnu Dileep to the Baylor College of Medicine from the Massachusetts Institute of Technology (MIT), where he is a postdoctoral fellow. His work includes the study of cancer genomes.

CPRIT also handed out more than $56.5 million in grants and awards to seven institutions in the Houston area. Here’s the rundown:

  • MD Anderson Cancer Center — Nearly $25.6 million
  • Baylor College of Medicine — Nearly $11.5 million
  • University of Texas Health Science Center at Houston — More than $6 million
  • Rice University — $4 million
  • University of Texas Medical Branch at Galveston — More than $3.5 million
  • Methodist Hospital Research Institute — More than $3.3 million
  • University of Houston — $1.4 million

Dr. Pavan Reddy, a CPRIT scholar who is a professor at the Baylor College of Medicine and director of its Dan L Duncan Comprehensive Cancer Care Center, says the CPRIT funding “will help our investigators take chances and explore bold ideas to make innovative discoveries.”

The Houston-area funding was part of nearly $99 million in grants and awards that CPRIT recently approved.

Houston Methodist's cardiovascular sciences, orthopedics and RNA therapeutics research programs will be the first to occupy the new space. Photo via houstonmethodist.org

Houston Methodist signs on at new TMC Helix Park building

moving in

Texas medical giant Houston Methodist is the latest to join the Dynamic One building within TMC Helix Park.

The hospital announced that it has signed a 75,800-square-foot lease in the building and will take over two floors of biomedical research laboratories. Houston Methodist's cardiovascular sciences, orthopedics and RNA therapeutics research programs will be the first to occupy the space.

“We are always focused on translating innovative medical discoveries into viable therapies for patients. These highly entrepreneurial programs, which translate these discoveries to the bedside, are a natural fit within the emerging biotechnology ecosystem that the TMC is cultivating,” Edward Jones, president and CEO of Houston Methodist Research Institute, said in the announcement.

Houston Methodist joins anchor tenant Baylor College of Medicine in the state-of-the-art building, which opened in Nov. 2023.

The 12-story Dynamic One building features lab space, offices, restaurants, and stores. It represents the first of four buildings planned for the 37-acre TMC Helix Park and was one of the largest life sciences projects in the U.S. set to come online last year.

Developers are slated to open three more move-in-ready Beacon Ready Labs in the building this summer, ranging from 9,000 to 15,000 square feet.

“We are excited to welcome Houston Methodist to this space; their commitment to bench to bedside innovation and track record of transformative new discoveries aligns with our vision for the campus,” William McKeon, president and CEO of the Texas Medical Center, said in a statement. “Beacon Capital has been an outstanding partner in the development of TMC Helix Park, lending their insights to our efforts to design a campus that would seamlessly blend institutions and industry.”

TMC Helix Park officially opened last October with the launch of the TMC3 Collaborative Building. The 250,000-square-foot building anchors the campus and houses research initiatives from the four founding partners: Texas Medical Center, The University of Texas MD Anderson Cancer Center, Texas A&M University Health Science Center, and The University of Texas Health Science Center at Houston.

UTHealth Houston also broke ground on its 350,000-square-foot tower on the campus last summer. It's slated to open in time for the 2026 Fall semester. And TMC unveiled plans for the fourth and final component of Helix Park, the TMC BioPort, in 2022.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Rice University's edtech company receives $90M to lead NSF research hub

major collaboration

An educational technology company based out of Rice University has received $90 million to create and lead a research and development hub for inclusive learning and education research. It's the largest research award in the history of the university.

OpenStax received the grant funding from the U.S. National Science Foundation for a five-year project create the R&D hub called SafeInsights, which "will enable extensive, long-term research on the predictors of effective learning while protecting student privacy," reads a news release from Rice. It's the NSF's largest single investment commitment to national sale education R&D infrastructure.

“We are thrilled to announce an investment of $90 million in SafeInsights, marking a significant step forward in our commitment to advancing scientific research in STEM education,” NSF Director Sethuraman Panchanathan says in the release. “There is an urgent need for research-informed strategies capable of transforming educational systems, empowering our nation’s workforce and propelling discoveries in the science of learning.

"By investing in cutting-edge infrastructure and fostering collaboration among researchers and educators, we are paving the way for transformative discoveries and equitable opportunities for learners across the nation.”

SafeInsights is funded through NSF’s Mid-scale Research Infrastructure-2 (Mid-scale RI-2) program and will act as a central hub for 80 partners and collaborating institutions.

“SafeInsights represents a pivotal moment for Rice University and a testament to our nation’s commitment to educational research,” Rice President Reginald DesRoches adds. “It will accelerate student learning through studies that result in more innovative, evidence-based tools and practices.”

Richard Baraniuk, who founded OpenStax and is a Rice professor, will lead SafeInsights. He says he hopes the initiative will allow progress to be made for students learning in various contexts.

“Learning is complex," Baraniuk says in the release. "Research can tackle this complexity and help get the right tools into the hands of educators and students, but to do so, we need reliable information on how students learn. Just as progress in health care research sparked stunning advances in personalized medicine, we need similar precision in education to support all students, particularly those from underrepresented and low-income backgrounds.”

OpenStax awarded $90M to lead NSF research hub for transformational learning and education researchwww.youtube.com

2 Houston startups selected by US military for geothermal projects

hot new recruits

Two clean energy companies in Houston have been recruited for geothermal projects at U.S. military installations.

Fervo Energy is exploring the potential for a geothermal energy system at Naval Air Station Fallon in Nevada.

Meanwhile, Sage Geosystems is working on an exploratory geothermal project for the Army’s Fort Bliss post in Texas. The Bliss project is the third U.S. Department of Defense geothermal initiative in the Lone Star State.

“Energy resilience for the U.S. military is essential in an increasingly digital and electric world, and we are pleased to help the U.S. Army and [the Defense Innovation Unit] to support energy resilience at Fort Bliss,” Cindy Taff, CEO of Sage, says in a news release.

A spokeswoman for Fervo declined to comment.

Andy Sabin, director of the Navy’s Geothermal Program Office, says in a military news release that previous geothermal exploration efforts indicate the Fallon facility “is ideally suited for enhanced geothermal systems to be deployed onsite.”

As for the Fort Bliss project, Michael Jones, a project director in the Army Office of Energy Initiatives, says it’ll combine geothermal technology with innovations from the oil and gas sector.

“This initiative adds to the momentum of Texas as a leader in the ‘geothermal anywhere’ revolution, leveraging the robust oil and gas industry profile in the state,” says Ken Wisian, associate director of the Environmental Division at the U.S. Bureau of Economic Geology.

The Department of Defense kicked off its geothermal initiative in September 2023. Specifically, the Army, Navy, and Defense Innovation Unit launched four exploratory geothermal projects at three U.S. military installations.

One of the three installations is the Air Force’s Joint Base San Antonio. Canada-based geothermal company Eavor is leading the San Antonio project.

Another geothermal company, Atlanta-based Teverra, was tapped for an exploratory geothermal project at the Army’s Fort Wainwright in Alaska. Teverra maintains an office in Houston.

------

This article originally ran on EnergyCapital.